Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Amortization of Deferred Charges (2016)

Historic Amortization of Deferred Charges for United Therapeutics (UTHR) over the last 8 years, with Q1 2016 value amounting to $100000.0.

  • United Therapeutics' Amortization of Deferred Charges fell 9500.0% to $100000.0 in Q1 2016 from the same period last year, while for Jun 2016 it was $941000.0, marking a year-over-year decrease of 9146.41%. This contributed to the annual value of $5.9 million for FY2015, which is 5230.41% down from last year.
  • Per United Therapeutics' latest filing, its Amortization of Deferred Charges stood at $100000.0 for Q1 2016, which was down 9500.0% from $433000.0 recorded in Q4 2015.
  • United Therapeutics' 5-year Amortization of Deferred Charges high stood at $3.4 million for Q3 2014, and its period low was $100000.0 during Q1 2016.
  • For the 5-year period, United Therapeutics' Amortization of Deferred Charges averaged around $2.5 million, with its median value being $3.0 million (2012).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 4750.23% in 2013, then plummeted by 9500.0% in 2016.
  • Quarter analysis of 5 years shows United Therapeutics' Amortization of Deferred Charges stood at $2.2 million in 2012, then surged by 47.5% to $3.2 million in 2013, then decreased by 21.98% to $2.5 million in 2014, then crashed by 82.6% to $433000.0 in 2015, then crashed by 76.91% to $100000.0 in 2016.
  • Its Amortization of Deferred Charges was $100000.0 in Q1 2016, compared to $433000.0 in Q4 2015 and $408000.0 in Q3 2015.